Covid19 Primer

Title	Date	Topic	Relevance
Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial Aleksandr V. Kudriavtsev et al in vaccines (4.422) Source crossref_works_2020_03_25	Feb 01, 2023	Placebo-controlled & Randomized	0.4
Voice-Based Screening for SARS-CoV-2 Exposure in Cardiovascular Clinics (VOICE-COVID-19-II): Protocol for a Randomized Controlled Trial Emily Oulousian et al in jmir research protocols Source crossref_works_2020_03_25	Jan 31, 2023	Placebo-controlled & Randomized	0.5
A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection Amit Singla et al in plos one (3.24) Source crossref_works_2020_03_25	Jan 30, 2023	Placebo-controlled & Randomized	0.8
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi Nawal Al Kaabi et al in vaccines (4.422) Source crossref_works_2020_03_25	Jan 30, 2023	Placebo-controlled & Randomized	0.4
Meplazumab in hospitalized adults with severe COVID-19 (DEFLECT): a multicenter, seamless phase 2/3, randomized, third-party double-blind clinical trial Huijie Bian et al in signal transduction and targeted therapy (18.187) Source crossref_works_2020_03_25	Jan 30, 2023	Placebo-controlled & Randomized	0.2
Randomized Controlled Trial Evaluating the Benefit of a Novel Clinical Decision Support System for the Management of COVID-19 Patients in Home Quarantine: A Study Protocol Irene Alcoceba-Herrero et al in international journal of environmental research and public health (3.39) Source crossref_works_2020_03_25	Jan 28, 2023	Placebo-controlled & Randomized	0.2
Efficacy and safety of metabolic interventions for the treatment of severe COVID-19: in vitro, observational, and non-randomized open label interventional study Avner Ehrlich et al in elife (8.14) Source crossref_works_2020_03_25	Jan 27, 2023	Placebo-controlled & Randomized	0.3
Effectiveness of tailored COVID-19 messages for vulnerable Australians: A study protocol Megan Jepson et al in plos one (3.24) Source crossref_works_2020_03_25	Jan 27, 2023	Placebo-controlled & Randomized	0.2
The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium Enya Daynes et al in trials (2.279) Source crossref_works_2020_03_25	Jan 26, 2023	Placebo-controlled & Randomized	0.2
Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults Pablo Forte-Soto et al in journal of infectious diseases (5.226) Source crossref_works_2020_03_25	Jan 23, 2023	Placebo-controlled & Randomized	0.5